Zoledronic acid once-yearly : what role in the prevention of non-vertebral osteoporotic fractures?
Doggrell, Sheila (2010) Zoledronic acid once-yearly : what role in the prevention of non-vertebral osteoporotic fractures? Clinical Medicine Insights: Therapeutics, 2010(2), pp. 539-547.
Osteoporosis is the most common bone disease. Low levels of oestrogens or testosterone are risk factors for primary osteoporosis. The most common cause of secondary osteoporosis is glucocorticoid treatment, but there are many other secondary causes of osteoporosis. Osteoporosis can be secondary to anti-oestrogen treatment for hormone-sensitive breast cancer and to androgen-deprivation therapy for prostate cancer. Zoledronic is the most potent bisphosphonate at inhibiting bone resorption. In osteoporosis, zoledronic acid increases bone mineral density for at least a year after a single intravenous administration. The efficacy and safety of extended release (once-yearly) zoledronic acid in the treatment of osteoporosis is reviewed.
Impact and interest:
Citation counts are sourced monthly from and citation databases.
Citations counts from theindexing service can be viewed at the linked Google Scholar™ search.
|Item Type:||Journal Article|
|Keywords:||zoledronic acid once-yearly, fractures, , osteoporosis, , safety,|
|Subjects:||Australian and New Zealand Standard Research Classification > MEDICAL AND HEALTH SCIENCES (110000) > PHARMACOLOGY AND PHARMACEUTICAL SCIENCES (111500) > Clinical Pharmacology and Therapeutics (111502)|
|Divisions:||Past > QUT Faculties & Divisions > Faculty of Science and Technology
Past > Schools > Medical Sciences
|Copyright Owner:||Copyright 2010 the author, publisher and licensee Libertas Academica Ltd.|
|Copyright Statement:||This is an open access article. Unrestricted non-commercial use is permitted provided the original work is properly cited. The authors grant exclusive rights to all commercial reproduction and distribution to Libertas Academica. Commercial reproduction and distribution rights are reserved by Libertas Academica. No unauthorised commercial use permitted without express consent of Libertas Academica. Contact email@example.com for further information.|
|Deposited On:||03 Nov 2010 00:13|
|Last Modified:||03 Nov 2010 14:57|
Repository Staff Only: item control page